NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis $5.67 0.00 (0.00%) As of 10/7/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About scPharmaceuticals Stock (NASDAQ:SCPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get scPharmaceuticals alerts:Sign Up Key Stats Today's Range$5.67▼$5.6750-Day Range$4.45▼$5.7552-Week Range$1.94▼$6.28VolumeN/AAverage Volume1.99 million shsMarket Capitalization$302.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.78Consensus RatingReduce Company Overview scPharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing innovative therapies for sickle cell disease. The company’s lead product candidate, SC411, is an investigational intravenous formulation of a hemoglobin polymerization inhibitor designed to rapidly increase hemoglobin oxygen affinity and potentially reduce the severity and duration of vaso‐occlusive crises. By delivering a water‐soluble prodrug directly into the bloodstream, scPharmaceuticals aims to address an acute unmet need in emergency and inpatient settings where swift intervention can improve patient outcomes. In addition to SC411, scPharmaceuticals is advancing a pipeline of small‐molecule candidates that target different aspects of red blood cell pathology in sickle cell disease. The company’s research and development efforts leverage proprietary prodrug technology to enhance delivery and bioavailability, with the goal of providing both acute crisis interventions and chronic disease management options. scPharmaceuticals collaborates with academic institutions and clinical research organizations to conduct Phase 1 studies and plans to initiate later‐stage trials upon successful completion of early safety and pharmacokinetic assessments. Headquartered in Cambridge, Massachusetts, scPharmaceuticals was founded to translate cutting‐edge science into practical treatments for patients suffering from sickle cell disease. The company’s leadership team comprises industry veterans with experience in hematology, drug development and regulatory affairs. While initially focused on the U.S. market, scPharmaceuticals has stated its intention to expand clinical programs internationally as it progresses toward potential product approvals.AI Generated. May Contain Errors. Read More scPharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreSCPH MarketRank™: scPharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 201st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingReduce Consensus RatingscPharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialscPharmaceuticals has a consensus price target of $7.78, representing about 37.3% upside from its current price of $5.67.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about scPharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 21.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about scPharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.52% of the outstanding shares of scPharmaceuticals have been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 16.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.12 Percentage of Shares Shorted1.52% of the outstanding shares of scPharmaceuticals have been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 16.87%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentscPharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.78% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about scPharmaceuticals' insider trading history. Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCPH Stock News HeadlinesMannKind completes acquisition of scPharmaceuticalsOctober 7, 2025 | msn.comscPharmaceuticals Completes Merger and Delists from NasdaqOctober 7, 2025 | msn.comDARPA Set to Trigger New Boom: Buy These 3 StocksBy the end of this month, DARPA — the government agency that invented the internet — is expected to make a major quantum computing announcement that could send three little-known quantum stocks soaring.October 14 at 2:00 AM | Brownstone Research (Ad)scPharmaceuticals Issues Promissory Note to MannKindSeptember 25, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHSeptember 16, 2025 | businesswire.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31, 2025 | finance.yahoo.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSee More Headlines SCPH Stock Analysis - Frequently Asked Questions How have SCPH shares performed this year? scPharmaceuticals' stock was trading at $3.54 on January 1st, 2025. Since then, SCPH shares have increased by 60.2% and is now trading at $5.67. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals, Inc. (NASDAQ:SCPH) announced its earnings results on Thursday, August, 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. The company earned $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative trailing twelve-month return on equity of 1,647.86% and a negative net margin of 183.55%. Read the conference call transcript. When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/07/2025Today10/14/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCPH CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees30Year Founded2014Price Target and Rating Average Price Target for scPharmaceuticals$7.78 High Price Target$12.00 Low Price Target$5.35 Potential Upside/Downside+37.3%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$85.15 million Net Margins-183.55% Pretax Margin-183.55% Return on Equity-1,647.86% Return on Assets-71.76% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.14 Sales & Book Value Annual Sales$49.97 million Price / Sales6.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book21.00Miscellaneous Outstanding Shares53,298,000Free Float50,750,000Market Cap$302.20 million OptionableOptionable Beta0.31 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SCPH) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.